SATAI Announces $1.045 Million Emerging Technology Fund Investment in Azaya Therapeutics, Inc.  
9/30/2009 9:26:01 AM

SAN ANTONIO--(BUSINESS WIRE)--SATAI ( and the South Texas Regional Center of Innovation and Commercialization ( today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.